## Andrea Salzano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8307139/publications.pdf Version: 2024-02-01

		94433	114465
146	4,695	37	63
papers	citations	h-index	g-index
153	153	153	5258
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Growth Hormone and the Heart. Endocrine Reviews, 1994, 15, 555-573.	20.1	493
2	Left Ventricular Diastolic Dysfunction in Patients with Subclinical Hypothyroidism. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2064-2067.	3.6	280
3	Differential Cardiac Effects of Growth Hormone and Insulin-like Growth Factor1 in the Rat. Circulation, 1996, 93, 800-809.	1.6	246
4	Growth Hormone Attenuates Early Left Ventricular Remodeling and Improves Cardiac Function in Rats With Large Myocardial Infarction. Journal of the American College of Cardiology, 1997, 29, 1109-1116.	2.8	153
5	Insulin-like Growth Factor-1 but Not Growth Hormone Augments Mammalian Myocardial Contractility by Sensitizing the Myofilament to Ca <sup>2+</sup> Through a Wortmannin-Sensitive Pathway. Circulation Research, 1998, 83, 50-59.	4.5	149
6	Metformin Prevents the Development of Chronic Heart Failure in the SHHF Rat Model. Diabetes, 2012, 61, 944-953.	0.6	112
7	GH and the cardiovascular system: an update on a topic at heart. Endocrine, 2015, 48, 25-35.	2.3	111
8	Cardiovascular abnormalities in Klinefelter Syndrome. International Journal of Cardiology, 2013, 168, 754-759.	1.7	89
9	Cardiovascular involvement in patients affected by acromegaly: An appraisal. International Journal of Cardiology, 2013, 167, 1712-1718.	1.7	82
10	Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study. American Journal of Gastroenterology, 2018, 113, 368-375.	0.4	82
11	Growth hormone, acromegaly, and heart failure: an intricate triangulation. Clinical Endocrinology, 2003, 59, 660-671.	2.4	79
12	MANAGEMENT OF ENDOCRINE DISEASE: Klinefelter syndrome, cardiovascular system, and thromboembolic disease: review of literature and clinical perspectives. European Journal of Endocrinology, 2016, 175, R27-R40.	3.7	79
13	Right ventricular-arterial uncoupling independently predicts survival in COVID-19 ARDS. Critical Care, 2020, 24, 670.	5.8	77
14	Growth Hormone Deficiency in Patients with Chronic Heart Failure and Beneficial Effects of Its Correction. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3329-3336.	3.6	71
15	Takotsubo cardiomyopathy: an integrated multi-imaging approach. European Heart Journal Cardiovascular Imaging, 2014, 15, 366-377.	1.2	69
16	Heart failure management during the <scp>COVID</scp> â€19 outbreak in Italy: a telemedicine experience from a heart failure university tertiary referral centre. European Journal of Heart Failure, 2020, 22, 1048-1050.	7.1	67
17	Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study. Clinical Research in Cardiology, 2016, 105, 912-920.	3.3	63
18	Takotsubo Cardiomyopathy. Heart Failure Clinics, 2013, 9, 249-266.	2.1	61

2

#	Article	IF	CITATIONS
19	Growth hormone prolongs survival in experimental postinfarction heart failure. Journal of the American College of Cardiology, 2003, 41, 2154-2163.	2.8	60
20	Growth Hormone Deficiency Is Associated with Worse Cardiac Function, Physical Performance, and Outcome in Chronic Heart Failure: Insights from the T.O.S.CA. GHD Study. PLoS ONE, 2017, 12, e0170058.	2.5	59
21	Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure. Cardiovascular Research, 2003, 58, 555-564.	3.8	57
22	Growth Hormone Replacement Delays the Progression of Chronic Heart Failure Combined With Growth Hormone Deficiency. JACC: Heart Failure, 2013, 1, 325-330.	4.1	57
23	Cardiovascular Abnormalities and Impaired Exercise Performance in Adolescents With Congenital Adrenal Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 644-652.	3.6	51
24	Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial. European Heart Journal, 2021, 42, 2284-2295.	2.2	51
25	Cardiovascular Abnormalities in Transgenic Mice With Reduced Brown Fat. Circulation, 1999, 100, 2177-2183.	1.6	49
26	A preliminary randomized study of growth hormone administration in Becker and Duchenne muscular dystrophies. European Heart Journal, 2003, 24, 664-672.	2.2	49
27	Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. International Journal of Cardiology, 2015, 195, 19-26.	1.7	46
28	Multiple hormone deficiencies in chronic heart failure. International Journal of Cardiology, 2015, 184, 421-423.	1.7	46
29	Polypharmacy in older people: lessons from 10Âyears of experience with the REPOSIÂregister. Internal and Emergency Medicine, 2018, 13, 1191-1200.	2.0	45
30	Klinefelter syndrome, insulin resistance, metabolic syndrome, and diabetes: review of literature and clinical perspectives. Endocrine, 2018, 61, 194-203.	2.3	44
31	The GH/IGF-1 Axis in Chronic Heart Failure. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2013, 13, 76-91.	1.2	43
32	Multiple hormone deficiency syndrome in heart failure with preserved ejection fraction. International Journal of Cardiology, 2016, 225, 1-3.	1.7	42
33	Defining Aging Phenotypes and Related Outcomes: Clues to Recognize Frailty in Hospitalized Older Patients. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 72, glw188.	3.6	41
34	Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.CA. Registry. Internal and Emergency Medicine, 2018, 13, 661-671.	2.0	41
35	SOCS1 gene transfer accelerates the transition to heart failure through the inhibition of the gp130/JAK/STAT pathway. Cardiovascular Research, 2012, 96, 381-390.	3.8	40
36	Editor's Choice-Biomarkers of acute cardiovascular and pulmonary diseases. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 416-433.	1.0	39

#	Article	IF	CITATIONS
37	Physiologic correlates of tricuspid annular plane systolic excursion in 1168 healthy subjects. International Journal of Cardiology, 2016, 223, 736-743.	1.7	39
38	Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). Respiratory Research, 2018, 19, 258.	3.6	39
39	Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit. Movement Disorders, 2011, 26, 739-742.	3.9	38
40	Hormone replacement therapy in heart failure. Current Opinion in Cardiology, 2015, 30, 277-284.	1.8	38
41	Prevention of Cardiovascular Disease: Screening for Magnesium Deficiency. Cardiology Research and Practice, 2019, 2019, 1-10.	1.1	36
42	Supraphysiological Doses of GH Induce Rapid Changes in Cardiac Morphology and Function. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1654-1659.	3.6	35
43	Detectable interleukin-9 plasma levels are associated with impaired cardiopulmonary functional capacity and all-cause mortality in patients with chronic heart failure. International Journal of Cardiology, 2016, 209, 114-117.	1.7	33
44	Gender-related differences in pulmonary arterial hypertension targeted drugs administration. Pharmacological Research, 2016, 114, 103-109.	7.1	33
45	Combined use of trimethylamine N-oxide with BNP for risk stratification in heart failure with preserved ejection fraction: findings from the DIAMONDHFpEF study. European Journal of Preventive Cardiology, 2020, 27, 2159-2162.	1.8	32
46	Effects of Growth Hormone on Exercise Capacity and Cardiopulmonary Performance in Patients with Chronic Heart Failure. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4218-4223.	3.6	30
47	Prevention and treatment of peritoneal adhesions in patients affected by vascular diseases following surgery: a review of the literature. Open Medicine (Poland), 2016, 11, 106-114.	1.3	29
48	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. Internal and Emergency Medicine, 2018, 13, 651-660.	2.0	29
49	IGF-1 predicts survival in chronic heart failure. Insights from the T.O.S.CA. (Trattamento Ormonale) Tj ETQq1 1 C	).784314 ı 1.7	gBT ¦Overlo⊂
50	Ethnic differences in association of outcomes with trimethylamine Nâ€oxide in acute heart failure patients. ESC Heart Failure, 2020, 7, 2373-2378.	3.1	27
51	Long-Term Cardiovascular Effects of Levothyroxine Therapy in Young Adults with Congenital Hypothyroidism. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2486-2491.	3.6	26
52	<scp>L</scp> ongâ€ŧerm effect of epoetin alfa on clinical and biochemical markers in friedreich ataxia. Movement Disorders, 2016, 31, 734-741.	3.9	26
53	Multiple hormonal and metabolic deficiency syndrome predicts outcome in heart failure: the T.O.S.CA. Registry. European Journal of Preventive Cardiology, 2021, 28, 1691-1700.	1.8	26
54	Geographical location affects the levels and association of trimethylamine Nâ€oxide with heart failure mortality in BIOSTATâ€CHF: a postâ€hoc analysis. European Journal of Heart Failure, 2019, 21, 1291-1294.	7.1	25

#	Article	IF	CITATIONS
55	Association of gut-related metabolites with outcome in acute heart failure. American Heart Journal, 2021, 234, 71-80.	2.7	25
56	A Focused Review of Gender Differences in Antithrombotic Therapy. Current Medicinal Chemistry, 2017, 24, 2576-2588.	2.4	25
57	Reference Ranges for and Determinants of Right Ventricular Area in Healthy Adults by Two-Dimensional Echocardiography. Respiration, 2015, 89, 284-293.	2.6	24
58	Imaging the right heart pulmonary circulation unit: Insights from advanced ultrasound techniques. Echocardiography, 2017, 34, 1216-1231.	0.9	24
59	Effects of long-term l-thyroxine treatment on endothelial function and arterial distensibility in young adults with congenital hypothyroidism. European Journal of Endocrinology, 2010, 162, 289-294.	3.7	23
60	Echocardiography and Heart Failure: A Glimpse of the Right Heart. Echocardiography, 2015, 32, S95-107.	0.9	23
61	Matrix-assisted laser desorption ionisation (MALDI) mass spectrometry (MS): basics and clinical applications. Clinical Chemistry and Laboratory Medicine, 2020, 58, 883-896.	2.3	23
62	Carotid plaque detection improves the predictive value of CHA2DS2-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study. International Journal of Cardiology, 2017, 231, 143-149.	1.7	22
63	The Gut Axis Involvement in Heart Failure. Heart Failure Clinics, 2020, 16, 23-31.	2.1	21
64	Growth Hormone Therapy in Heart Failure. Heart Failure Clinics, 2018, 14, 501-515.	2.1	20
65	Biomarkers in Pulmonary Hypertension. Heart Failure Clinics, 2018, 14, 393-402.	2.1	20
66	Chronic growth hormone treatment in normal rats reduces post-prandial skeletal muscle plasma membrane GLUT1 content, but not glucose transport or GLUT4 expression and localization. Biochemical Journal, 1996, 315, 959-963.	3.7	19
67	An unusual case of dilated cardiomyopathy associated with partial hypopituitarism. Internal and Emergency Medicine, 2012, 7, 85-87.	2.0	19
68	Implementation of the Frailty Index in hospitalized older patients: Results from the REPOSI register. European Journal of Internal Medicine, 2018, 56, 11-18.	2.2	19
69	Primary prevention of cancer-related thrombosis: Special focus on ambulatory patients. International Journal of Cardiology, 2014, 173, 583-584.	1.7	18
70	Reference Ranges and Determinants of Tricuspid Regurgitation Velocity in Healthy Adults Assessed by Two-Dimensional Doppler-Echocardiography. Respiration, 2018, 96, 425-433.	2.6	18
71	Reference ranges and determinants of right ventricle outflow tract acceleration time in healthy adults by two-dimensional echocardiography. International Journal of Cardiovascular Imaging, 2017, 33, 219-226.	1.5	17
72	Prognostic value of degree and types of anaemia on clinical outcomes for hospitalised older patients. Archives of Gerontology and Geriatrics, 2017, 69, 21-30.	3.0	17

#	Article	IF	CITATIONS
73	Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study. Drugs and Aging, 2018, 35, 365-373.	2.7	17
74	Metabolic Syndrome in Heart Failure. Heart Failure Clinics, 2019, 15, 349-358.	2.1	17
75	The T.O.S.CA. Project: Research, Education and Care. Monaldi Archives for Chest Disease, 2011, 76, 198-203.	0.6	15
76	The Right Heart International Network (RIGHT-NET). Heart Failure Clinics, 2018, 14, 443-465.	2.1	15
77	Combined effects of growth hormone and testosterone replacement treatment in heart failure. ESC Heart Failure, 2019, 6, 1216-1221.	3.1	15
78	Exercise Intolerance in Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2021, 17, 397-413.	2.1	15
79	High circulating levels of CCL2 in patients with Klinefelter's syndrome. Clinical Endocrinology, 2014, 80, 465-467.	2.4	14
80	The role of curcumin in liver diseases. Archives of Medical Science, 2019, 15, 1608-1620.	0.9	14
81	Biomarkers and Imaging. Heart Failure Clinics, 2019, 15, 321-331.	2.1	14
82	Testosterone therapy and cardiovascular diseases. Cardiovascular Research, 2022, 118, 2039-2057.	3.8	14
83	Exercise training modalities in chronic heart failure: does high intensity aerobic interval training make the difference?. Monaldi Archives for Chest Disease, 2016, 86, 754.	0.6	13
84	Growth Hormone as Biomarker in Heart Failure. Heart Failure Clinics, 2018, 14, 65-74.	2.1	13
85	The impact of gender in cardiovascular medicine: Lessons from the gender/sex-issue in heart failure. Monaldi Archives for Chest Disease, 2018, 88, 988.	0.6	12
86	Hormonal Replacement Therapy in Heart Failure. Heart Failure Clinics, 2019, 15, 377-391.	2.1	12
87	Impact of acute choline loading on circulating trimethylamine N-oxide levels. European Journal of Preventive Cardiology, 2019, 26, 1899-1902.	1.8	12
88	Circulating cell-free DNA levels are associated with adverse outcomes in heart failure: testing liquid biopsy in heart failure. European Journal of Preventive Cardiology, 2020, 28, e28-e31.	1.8	12
89	Pattern of inâ€hospital changes in drug use in the older people from 2010 to 2016. Pharmacoepidemiology and Drug Safety, 2017, 26, 1534-1539.	1.9	11
90	Growth hormone- and pressure overload-induced cardiac hypertrophy evoke different responses to ischemia-reperfusion and mechanical stretch. Growth Hormone and IGF Research, 2006, 16, 29-40.	1.1	10

#	Article	lF	CITATIONS
91	Biomarkers in Heart Failure. Heart Failure Clinics, 2021, 17, 223-243.	2.1	10
92	Myocardial expression of somatotropic axis, adrenergic signalling, and calcium handling genes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. ESC Heart Failure, 2021, 8, 1681-1686.	3.1	10
93	Laparoscopic single site (LESS) and classic video-laparoscopic cholecystectomy in the elderly: A single centre experience. International Journal of Surgery, 2016, 33, S1-S3.	2.7	9
94	Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina) Tj ETQq0	0 @ngBT /(	Overlock 10 T
95	Multiple hormone deficiency syndrome: a novel topic in chronic heart failure. Future Science OA, 2018, 4, FSO311.	1.9	9
96	Pulmonary Embolism. Heart Failure Clinics, 2020, 16, 317-330.	2.1	9
97	Age-changes in right ventricular function–pulmonary circulation coupling: from pediatric to adult stage in 1899 healthy subjects. The RIGHT Heart International NETwork (RIGHT-NET). International Journal of Cardiovascular Imaging, 2021, 37, 3399-3411.	1.5	9
98	Right Side of the Heart Pulmonary Circulation Unit Involvement in Left-Sided Heart Failure. Chest, 2022, 161, 535-551.	0.8	9
99	Effects of canrenone on myocardial reactive fibrosis in a rat model of postinfarction heart failure. Cardiovascular Drugs and Therapy, 2002, 16, 195-201.	2.6	8
100	Pregabalin-induced first degree atrioventricular block in a young patient treated for pain from extrapulmonary tuberculosis. Monaldi Archives for Chest Disease, 2017, 87, 838.	0.6	8
101	The impairment of the Growth Hormone/Insulin-like growth factor 1 (IGF-1) axis in heart failure: A possible target for future therapy. Monaldi Archives for Chest Disease, 2018, 88, 975.	0.6	8
102	Reference values and correlates of right atrial volume in healthy adults by twoâ€dimensional echocardiography. Echocardiography, 2018, 35, 1097-1107.	0.9	8
103	Preoperative Assessment and Management of Cardiovascular Risk in Patients Undergoing Non-Cardiac Surgery: Implementing a Systematic Stepwise Approach during the COVID-19 Pandemic Era. Journal of Cardiovascular Development and Disease, 2021, 8, 126.	1.6	8
104	Implications of serial measurements of natriuretic peptides in heart failure: insights from <scp>BIOSTAT HF</scp> . European Journal of Heart Failure, 2020, 22, 1486-1490.	7.1	7
105	A multicentric quality-control study of exercise Doppler echocardiography of the right heart and the pulmonary circulation. The RIGHT Heart International NETwork (RIGHT-NET). Cardiovascular Ultrasound, 2021, 19, 9.	1.6	7
106	Safety and feasibility of upper limb cardiopulmonary exercise test in Friedreich ataxia. European Journal of Preventive Cardiology, 2022, 29, 445-451.	1.8	7
107	Human heart shifts from IGF-1 production to utilization with chronic heart failure. Endocrine, 2019, 65, 714-716.	2.3	6
108	Additive Value of Biomarkers and Echocardiography to Stratify the Risk of Death in Heart Failure Patients with Reduced Ejection Fraction. Cardiology Research and Practice, 2019, 2019, 1-9.	1.1	6

#	Article	IF	CITATIONS
109	Anabolic Hormone Deficiencies in Heart Failure with Reduced or Preserved Ejection Fraction and Correlation with Plasma Total Antioxidant Capacity. International Journal of Endocrinology, 2020, 2020, 1-7.	1.5	6
110	Feasibility of semi-recumbent bicycle exercise Doppler echocardiography for the evaluation of the right heart and pulmonary circulation unit in different clinical conditions: the RIGHT heart international NETwork (RIGHT-NET). International Journal of Cardiovascular Imaging, 2021, 37, 2151-2167.	1.5	6
111	Association of gut-related metabolites with respiratory symptoms in COVID-19: A proof-of-concept study. Nutrition, 2022, 96, 111585.	2.4	6
112	Reference Ranges of Left Ventricular Hemodynamic Forces in Healthy Adults: A Speckle-Tracking Echocardiographic Study. Journal of Clinical Medicine, 2021, 10, 5937.	2.4	6
113	The Gut Axis Involvement in Heart Failure. Cardiology Clinics, 2022, 40, 161-169.	2.2	6
114	Physiologic Range of Myocardial Mechano-Energetic Efficiency among Healthy Subjects: Impact of Gender and Age. Journal of Personalized Medicine, 2022, 12, 996.	2.5	6
115	Progressive right ventricular dysfunction and exercise impairment in patients with heart failure and diabetes mellitus: insights from the T.O.S.CA. Registry. Cardiovascular Diabetology, 2022, 21, .	6.8	6
116	Bleeding related to non-vitamin K antagonist oral anticoagulants in emergency department: A "Real-world―snapshot from Southern Italy. On behalf of MIRC-NOAC study group. European Journal of Internal Medicine, 2018, 48, e21-e24.	2.2	5
117	Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids. Journal of the American Medical Directors Association, 2019, 20, 1313-1317.e9.	2.5	5
118	Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study. Medical Principles and Practice, 2019, 28, 501-508.	2.4	5
119	Management of cardiovascular complications in Klinefelter syndrome patients. Expert Review of Endocrinology and Metabolism, 2019, 14, 145-152.	2.4	5
120	Heart failure with preserved ejection fraction: Squaring the circle between comorbidities and cardiovascular abnormalities. European Journal of Internal Medicine, 2022, 99, 1-6.	2.2	5
121	Idiopathic pulmonary fibrosis telemedicine management during COVID-19 outbreak. Open Medicine (Poland), 2022, 17, 689-693.	1.3	5
122	Surrogate markers of gut dysfunction are related to heart failure severity and outcome–from the BIOSTAT-CHF consortium. American Heart Journal, 2022, 248, 108-119.	2.7	5
123	Testosterone treatment in chronic heart failure. Review of literature and future perspectives. Monaldi Archives for Chest Disease, 2018, 88, 976.	0.6	4
124	Are heart failure observational studies still useful? â€~No need to argue'*. European Journal of Preventive Cardiology, 2021, 28, 1006-1008.	1.8	4
125	Insulin-like growth factor-1 (IGF-1) as predictor of cardiovascular mortality in heart failure patients: data from the T.O.S.CA. registry. Internal and Emergency Medicine, 2022, 17, 1651-1660.	2.0	4
126	Biomarkers in Heart Failure and Associated Diseases. Disease Markers, 2019, 2019, 1-2.	1.3	3

#	Article	IF	CITATIONS
127	Anabolic Deficiencies in Heart Failure. Heart Failure Clinics, 2020, 16, 11-21.	2.1	3
128	Right-sided infective endocarditis and pulmonary embolism: a multicenter study. Monaldi Archives for Chest Disease, 2022, , .	0.6	3
129	Stability of erythropoietin repackaging in polypropylene syringes for clinical use. Saudi Pharmaceutical Journal, 2017, 25, 290-293.	2.7	2
130	Growth hormone in heart failure revisited: An old story retold. Monaldi Archives for Chest Disease, 2018, 88, 989.	0.6	2
131	Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients. European Journal of Internal Medicine, 2019, 68, e7-e11.	2.2	2
132	Biomarkers in Cardiovascular Disease: The Dilemma of Racial Differences. Journal of the American Heart Association, 2019, 8, e014295.	3.7	2
133	Gut Feeling. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1967-1969.	2.4	2
134	Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register. Internal and Emergency Medicine, 2019, 14, 1347-1352.	2.0	1
135	Letter to the Editor: "Cardiometabolic Biomarkers and Their Temporal Patterns Predict Poor Outcome in Chronic Heart Failure (Bio-SHiFT Study)― Journal of Clinical Endocrinology and Metabolism, 2019, 104, 734-735.	3.6	1
136	Risk stratification in hospitalized heart failure patients: do the RIGHT thing!. Internal and Emergency Medicine, 2019, 14, 1021-1023.	2.0	1
137	Emerging Comorbidities in Heart Failure. Heart Failure Clinics, 2020, 16, xiii-xv.	2.1	1
138	Effect of growth hormone treatment on circulating levels of NT-proBNP in patients with ischemic heart failure. Growth Hormone and IGF Research, 2020, 55, 101359.	1.1	1
139	The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of the REPOSI registry. Age and Ageing, 2021, 50, 498-504.	1.6	1
140	Targeting the gut microbiome in coronary artery disease. American Heart Journal, 2021, 236, 1-3.	2.7	1
141	Features and behavior of valvular abnormalities in adolescent and adult patients in mucopolysaccharidosis: an echocardiographic study. Monaldi Archives for Chest Disease, 2021, , .	0.6	1
142	Anabolic Deficiencies in Heart Failure. Cardiology Clinics, 2022, 40, 149-159.	2.2	1
143	Bowel Angiodysplasia and Myocardial Infarction secondary to an ischaemic imbalance: a case report. Open Medicine (Poland), 2015, 10, 543-548.	1.3	0
144	Cardiac size and function in children with subclinical hypothyroidism. Endocrine Abstracts, 0, , .	0.0	0

#	Article	IF	CITATIONS
145	Right Heart Pulmonary Circulation Unit Response to Exercise in Patients with Controlled Systemic Arterial Hypertension: Insights from the RIGHT Heart International NETwork (RIGHT-NET). Journal of Clinical Medicine, 2022, 11, 451.	2.4	0
146	Emerging Comorbidities in Heart Failure. Cardiology Clinics, 2022, 40, xi-xiv.	2.2	0